Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy Dynavax Technologies Corporation stock | $5.06

Own Dynavax Technologies Corporation stock in just a few minutes.

Fact checked

Dynavax Technologies Corporation is a biotechnology business based in the US. Dynavax Technologies Corporation shares (DVAX) are listed on the NASDAQ and all prices are listed in US Dollars. Dynavax Technologies Corporation employs 231 staff and has a trailing 12-month revenue of around USD$37.6 million.

How to buy shares in Dynavax Technologies Corporation

  1. Compare share trading platforms. If you're a beginner, look for a platform with low commissions, expert ratings and investment tools to track your portfolio. Narrow down top brands with our comparison table.
  2. Open and fund your brokerage account. Complete an application with your personal and financial details, like your ID and bank information. Fund your account with a bank transfer, credit card or debit card.
  3. Search for Dynavax Technologies Corporation. Find the stock by name or ticker symbol: DVAX. Research its history to confirm it's a solid investment against your financial goals.
  4. Purchase now or later. Buy today with a market order or use a limit order to delay your purchase until Dynavax Technologies Corporation reaches your desired price. To spread out your purchase, look into dollar-cost averaging, which smooths out buying at consistent intervals and amounts.
  5. Decide on how many to buy. At last close price of USD$5.06, weigh your budget against a diversified portfolio that can minimize risk through the market's ups and downs. You may be able to buy a fractional share of Dynavax Technologies Corporation, depending on your broker.
  6. Check in on your investment. Congratulations, you own a part of Dynavax Technologies Corporation. Optimize your portfolio by tracking how your stock — and even the business — performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights on directors and management that can affect your stock.

Dynavax Technologies Corporation share price

Use our graph to track the performance of DVAX stocks over time.

Dynavax Technologies Corporation shares at a glance

Information last updated 2020-12-27.
Latest market closeUSD$5.06
52-week rangeUSD$1.8 - USD$12.44
50-day moving average USD$4.7261
200-day moving average USD$5.9862
Wall St. target priceUSD$16
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) USD$-2.563

Buy Dynavax Technologies Corporation shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Stock trade fee Asset types Option trade fee Annual fee
Sofi Invest
$0
Stocks, ETFs, Cryptocurrency
N/A
0%
A free way to invest in stocks, ETFs and crypto.
Robinhood
$0
Stocks, Options, ETFs, Cryptocurrency
$0
0%
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
Moomoo
$0 for US stocks
Stocks, Options, ETFs
$0
Trade stocks on the US, Hong Kong, Shanghai and Shenzhen markets.
TD Ameritrade
$0
or $25 broker-assisted
Stocks
$0 + $0.65/contract,
or $25 broker-assisted
TD Ameritrade features $0 commission for online stock, but watch out for high short-term ETF and broker-assisted trading fees.
loading

Compare up to 4 providers

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Dynavax Technologies Corporation stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Dynavax Technologies Corporation price performance over time

Historical closes compared with the close of $5.06 from 2020-12-18

1 week (2021-01-08) 1.40%
1 month (2020-12-16) 9.29%
3 months (2020-10-15) 9.76%
6 months (2020-07-15) -45.94%
1 year (2020-01-15) -11.69%
2 years (2019-01-15) -57.97%
3 years (2018-01-12) 15.75
5 years (2016-01-15) 21.05

Dynavax Technologies Corporation financials

Revenue TTM USD$37.6 million
Gross profit TTM USD$-37,284,000
Return on assets TTM -15.77%
Return on equity TTM -178.03%
Profit margin -256.92%
Book value $0.629
Market capitalisation USD$581.7 million

TTM: trailing 12 months

Shorting Dynavax Technologies Corporation shares

There are currently 24.4 million Dynavax Technologies Corporation shares held short by investors – that's known as Dynavax Technologies Corporation's "short interest". This figure is 8.7% down from 26.7 million last month.

There are a few different ways that this level of interest in shorting Dynavax Technologies Corporation shares can be evaluated.

Dynavax Technologies Corporation's "short interest ratio" (SIR)

Dynavax Technologies Corporation's "short interest ratio" (SIR) is the quantity of Dynavax Technologies Corporation shares currently shorted divided by the average quantity of Dynavax Technologies Corporation shares traded daily (recently around 3.0 million). Dynavax Technologies Corporation's SIR currently stands at 8.11. In other words for every 100,000 Dynavax Technologies Corporation shares traded daily on the market, roughly 8110 shares are currently held short.

However Dynavax Technologies Corporation's short interest can also be evaluated against the total number of Dynavax Technologies Corporation shares, or, against the total number of tradable Dynavax Technologies Corporation shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Dynavax Technologies Corporation's short interest could be expressed as 0.22% of the outstanding shares (for every 100,000 Dynavax Technologies Corporation shares in existence, roughly 220 shares are currently held short) or 0.2961% of the tradable shares (for every 100,000 tradable Dynavax Technologies Corporation shares, roughly 296 shares are currently held short).

A SIR below 10% would generally be considered to indicate a fairly optimistic outlook for the share price, with fewer people currently willing to bet against Dynavax Technologies Corporation.

Find out more about how you can short Dynavax Technologies Corporation stock.

Dynavax Technologies Corporation share dividends

We're not expecting Dynavax Technologies Corporation to pay a dividend over the next 12 months.

Have Dynavax Technologies Corporation's shares ever split?

Dynavax Technologies Corporation's shares were split on a 1:10 basis on 10 November 2014. So if you had owned 10 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Dynavax Technologies Corporation shares – just the quantity. However, indirectly, the new 900% higher share price could have impacted the market appetite for Dynavax Technologies Corporation shares which in turn could have impacted Dynavax Technologies Corporation's share price.

Dynavax Technologies Corporation share price volatility

Over the last 12 months, Dynavax Technologies Corporation's shares have ranged in value from as little as $1.8 up to $12.44. A popular way to gauge a stock's volatility is its "beta".

DVAX.US volatility(beta: 1.4)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Dynavax Technologies Corporation's is 1.3984. This would suggest that Dynavax Technologies Corporation's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).

Dynavax Technologies Corporation overview

Dynavax Technologies Corporation, a biopharmaceutical company, focuses on leveraging the power of the body's innate and adaptive immune responses through toll-like receptor stimulation. The company markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older. Its immuno-oncology portfolio includes development stage products, such as SD-101 and DV281. Dynavax Technologies Corporation has a research collaboration with Clover Biopharmaceuticals; the University of Queensland and the Coalition for Epidemic Preparedness; and Sinovac Biotech Ltd. for the development of a vaccine candidate to prevent coronavirus (COVID-19). Dynavax Technologies Corporation has partnership with the Coalition for Epidemic Preparedness Innovations (CEPI) to create a vaccine against COVID-19 infection; a collaboration with Valneva SE to initiate a vaccine program for the coronavirus, COVID-19; and collaboration with Medicago to develop a novel adjuvanted COVID 19 vaccine candidate. The company was formerly known as Double Helix Corporation and changed its name to Dynavax Technologies Corporation in September 1996. Dynavax Technologies Corporation was founded in 1996 and is headquartered in Emeryville, California.

Frequently asked questions

More guides on Finder

Ask an Expert

You are about to post a question on finder.com:

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • finder.com is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked

Finder.com provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and finder.com Terms of Use.

Questions and responses on finder.com are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site